Scholarlink

<p>This study assessed [<sup>131</sup>I]I-PGV-0 as a potential targeted radiopharmaceutical for breast cancer treatment. The [<sup>131</sup>I]I-PGV-0 exhibited significantly enhanced cellular uptake compared to <sup>131</sup>I (30–50 times greater). MDA-MB-231 cells demonstrated higher susceptibility to the compound due to their radiosensitive ER-negative phenotype, while MCF7 cells displayed adaptive responses. Apoptotic observations confirmed the compound’s ability to induce significant cell death through targeted mechanisms. Molecular dynamics simulations revealed stable structural integrity with favorable RMSD and RMSF profiles, while biodistribution studies indicated accumulation in the thyroid and stomach. The [<sup>131</sup>I]I-PGV-0 demonstrates substantial promise as a targeted radiopharmaceutical for aggressive and resistant breast cancer subtypes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A dual approach to cancer therapy and diagnosis: in vitro, in vivo, and in silico study of 131I-labeled pentagamavunon-0

  • 期刊论文

  • 发表日期：

    2025年5月6日

查看全文
  • Alfian Mahardika Forentin,
  • Miftakul Munir,
  • Muhammad Basit Febrian,
  • Taufik Muhammad Fakih,
  • Rohmad Yudi Utomo,
  • Arni Aries,
  • Herlan Setiawan,
  • Ahsanal Fikri,
  • Sumandi Juliyanto,
  • Dwi Ramadhani,
  • Ratna Asmah Susidarti,
  • Muthi Ikawati,
  • Mukh Syaifudin,
  • Edy Meiyanto

摘要

This study assessed [131I]I-PGV-0 as a potential targeted radiopharmaceutical for breast cancer treatment. The [131I]I-PGV-0 exhibited significantly enhanced cellular uptake compared to 131I (30–50 times greater). MDA-MB-231 cells demonstrated higher susceptibility to the compound due to their radiosensitive ER-negative phenotype, while MCF7 cells displayed adaptive responses. Apoptotic observations confirmed the compound’s ability to induce significant cell death through targeted mechanisms. Molecular dynamics simulations revealed stable structural integrity with favorable RMSD and RMSF profiles, while biodistribution studies indicated accumulation in the thyroid and stomach. The [131I]I-PGV-0 demonstrates substantial promise as a targeted radiopharmaceutical for aggressive and resistant breast cancer subtypes.